176 related articles for article (PubMed ID: 30046671)
1. Endothelial barrier protective properties of low molecular weight heparin: A novel potential tool in the prevention of cancer metastasis?
Kevane B; Egan K; Allen S; Maguire P; Neary E; Lennon Á; Ní Áinle F
Res Pract Thromb Haemost; 2017 Jul; 1(1):23-32. PubMed ID: 30046671
[TBL] [Abstract][Full Text] [Related]
2. The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
Gockel LM; Ponert JM; Schwarz S; Schlesinger M; Bendas G
Molecules; 2018 Oct; 23(11):. PubMed ID: 30356007
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Sudha T; Phillips P; Kanaan C; Linhardt RJ; Borsig L; Mousa SA
Clin Exp Metastasis; 2012 Jun; 29(5):431-9. PubMed ID: 22415710
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
[TBL] [Abstract][Full Text] [Related]
5. Thrombin generation post elective caesarean section: effect of low molecular weight heparin.
Ismail SK; Norris L; Muttukrishna S; Higgins JR
Thromb Res; 2012 Nov; 130(5):799-803. PubMed ID: 22365560
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.
Mousa SA; Mohamed S
Thromb Haemost; 2004 Sep; 92(3):627-33. PubMed ID: 15351861
[TBL] [Abstract][Full Text] [Related]
7. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
8. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
Hiebert LM
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
[TBL] [Abstract][Full Text] [Related]
9. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Amirkhosravi A; Mousa SA; Amaya M; Francis JL
J Thromb Haemost; 2003 Sep; 1(9):1972-6. PubMed ID: 12941039
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
11. Sulfated non-anticoagulant low molecular weight heparin in the prevention of cancer and non-cancer associated thrombosis without compromising hemostasis.
Darwish NHE; Godugu K; Mousa SA
Thromb Res; 2021 Apr; 200():109-114. PubMed ID: 33582600
[TBL] [Abstract][Full Text] [Related]
12. A novel protein C-factor VII chimera provides new insights into the structural requirements for cytoprotective protease-activated receptor 1 signaling.
Gleeson EM; McDonnell CJ; Soule EE; Willis Fox O; Rushe H; Rehill A; Smith OP; O'Donnell JS; Preston RJS
J Thromb Haemost; 2017 Nov; 15(11):2198-2207. PubMed ID: 28834159
[TBL] [Abstract][Full Text] [Related]
13. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy.
Mousa SA; Mohamed S
Oncol Rep; 2004 Oct; 12(4):683-8. PubMed ID: 15375485
[TBL] [Abstract][Full Text] [Related]
15. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
[TBL] [Abstract][Full Text] [Related]
16. Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan.
Maddineni J; Ma Q; Hoppensteadt DA; Demir M; Manoni M; Cornelli U; Fareed J
Clin Appl Thromb Hemost; 2004 Jan; 10(1):27-37. PubMed ID: 14979402
[TBL] [Abstract][Full Text] [Related]
17. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
Nasser NJ; Sarig G; Brenner B; Nevo E; Goldshmidt O; Zcharia E; Li JP; Vlodavsky I
J Thromb Haemost; 2006 Mar; 4(3):560-5. PubMed ID: 16460439
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.
Mousa SA; Petersen LJ
Thromb Haemost; 2009 Aug; 102(2):258-67. PubMed ID: 19652876
[TBL] [Abstract][Full Text] [Related]
19. [Inhibitory effect of low molecular weight heparin on the secretion of vascular endothelial growth factor by tumor cells in vitro].
Sun Z; Hu ZL; Ning XH; Zhou JF; Shao YJ; Duan JH; Yang XD; Bai CM
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):826-30. PubMed ID: 20137346
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats.
Lauritzen B; Hedner U; Johansen PB; Tranholm M; Ezban M
J Thromb Haemost; 2008 May; 6(5):804-11. PubMed ID: 18315554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
